These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 26969090)

  • 21. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
    Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kusuda Y; Harada K; Sakai I; Fujisawa M
    Int J Clin Oncol; 2013 Feb; 18(1):81-6. PubMed ID: 22095244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A; Pavlik T; Melichar B; Puzanov I; Dusek L; Bortlicek Z; Vyzula R; Abrahamova J; Buchler T;
    Ann Oncol; 2012 Dec; 23(12):3137-3143. PubMed ID: 22700990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
    Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
    Chin J Cancer; 2017 Aug; 36(1):64. PubMed ID: 28789709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Wen T; Xiao H; Luo C; Huang L; Xiong M
    Oncotarget; 2017 Mar; 8(12):20441-20451. PubMed ID: 28099901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
    Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
    Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Rini BI; Stenzl A; Zdrojowy R; Kogan M; Shkolnik M; Oudard S; Weikert S; Bracarda S; Crabb SJ; Bedke J; Ludwig J; Maurer D; Mendrzyk R; Wagner C; Mahr A; Fritsche J; Weinschenk T; Walter S; Kirner A; Singh-Jasuja H; Reinhardt C; Eisen T
    Lancet Oncol; 2016 Nov; 17(11):1599-1611. PubMed ID: 27720136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Jang S; Zheng C; Tsai HT; Fu AZ; Barac A; Atkins MB; Freedman AN; Minasian L; Potosky AL
    Cancer; 2016 Jan; 122(1):124-30. PubMed ID: 26439451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK;
    Lancet Oncol; 2022 Sep; 23(9):1133-1144. PubMed ID: 36055304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
    Zhao F; Cella D; Manola J; DiPaola RS; Wagner LI; Haas NSB
    Support Care Cancer; 2018 Jun; 26(6):1889-1895. PubMed ID: 29274030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
    Ambring A; Björholt I; Lesén E; Stierner U; Odén A
    Med Oncol; 2013 Mar; 30(1):331. PubMed ID: 23254966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
    Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
    J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
    Zhang HL; Sheng XN; Li XS; Wang HK; Chi ZH; He ZS; Ye DW; Guo J
    BMC Cancer; 2017 Jan; 17(1):16. PubMed ID: 28056874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.